Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Reid W. Merryman(Harvard University), Alex F. Herrera(City of Hope), Michael A. Spinner(Stanford Medicine), Jakub Svoboda(UPMC Hillman Cancer Center), Ryan C. Lynch(Seattle Cancer Care Alliance), Jonathon B. Cohen(Emory University), Sunita Nathan(Rush University Medical Center), Kevin A. David(Rutgers, The State University of New Jersey), Robert Redd(Harvard University), Kami J. Maddocks(The Ohio State University), Robin Joyce(Beth Israel Deaconess Medical Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Yi‐Bin Chen(Massachusetts General Hospital), Vincent T. Ho(Dana-Farber Cancer Institute), Hatcher J. Ballard(University of Pennsylvania), Anurag K. Singh(University Medical Center), Michael Byrne(Vanderbilt University Medical Center), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Joseph P. McGuirk(University of Kansas Medical Center), Radhakrishnan Ramchandren(The Christie NHS Foundation Trust), Philippe Armand(Harvard University), Stephen M. Ansell(Mayo Clinic), Ranjana H. Advani(Stanford Medicine), Taiga Nishihori(Moffitt Cancer Center), Matthew J. Frigault(Harvard University), Veronika Bachanová(University of Minnesota), Steven Park(Levine Cancer Institute), Nadia Khan(Fox Chase Cancer Center), Jason T. Romancik(Emory University), Anthony V. Serritella(University of Chicago), Julio C. Chávez(Moffitt Cancer Center), Ann S. LaCasce(Otsuka (Japan)), Justin Darrah(Cedars-Sinai Medical Center), Anne Beaven(Duke Medical Center), Dipenkumar Modi(Wayne State University), Stephen D. Smith(Seattle Cancer Care Alliance), J. Kline(University of Chicago), Uttam K. Rao(Sarah Cannon), Maryam Rahimian(Beth Israel Deaconess Medical Center), Mansi Shah(University of North Carolina at Chapel Hill), Alma Habib(The Ohio State University), Shazia Nakhoda(Fox Chase Cancer Center)
Cited by 51
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k